UnitedHealth Group (UNH)
Market Price (11/5/2026): $411.85 | Market Cap: $369.0 BilInvestor Relations Sector: Health Care | Industry: Managed Health Care
UnitedHealth Group (UNH)
Market Price (11/5/2026): $411.85Market Cap: $369.0 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.6%, Dividend Yield is 2.2%, FCF Yield is 6.2% Stock buyback supportStock Buyback 3Y Total is 21 Bil Attractive cash flow generationCFO LTM is 26 Bil, FCF LTM is 23 Bil Low stock price volatilityVol 12M is 35% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. | Weak multi-year price returns2Y Excs Rtn is -54%, 3Y Excs Rtn is -99% | Weak revenue growthRev Chg QQuarterly Revenue Change % is -0.4% Key risksUNH key risks include [1] intense regulatory scrutiny and antitrust probes targeting its Medicare Advantage and Optum businesses, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.6%, Dividend Yield is 2.2%, FCF Yield is 6.2% |
| Stock buyback supportStock Buyback 3Y Total is 21 Bil |
| Attractive cash flow generationCFO LTM is 26 Bil, FCF LTM is 23 Bil |
| Low stock price volatilityVol 12M is 35% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -54%, 3Y Excs Rtn is -99% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -0.4% |
| Key risksUNH key risks include [1] intense regulatory scrutiny and antitrust probes targeting its Medicare Advantage and Optum businesses, Show more. |
Qualitative Assessment
AI Analysis | Feedback
UnitedHealth Group (UNH) stock has remained largely at the same level since 7/31/2026 because of the following key factors:
1. Deterioration in 2027 Medicare Star Ratings.
UnitedHealth Group's stock faced pressure following the October 8, 2026, publication of the 2027 Medicare Star Ratings by the Centers for Medicare & Medicaid Services (CMS). J.P. Morgan estimated that UnitedHealth's proportion of members in plans rated four stars or higher would decline significantly from 81% to approximately 67%. This anticipated reduction in ratings is projected to result in a substantial $1.5 billion revenue headwind in 2028 due to decreased quality bonus payments, which contributed to investor concern about future financial performance.
Show more
UnitedHealth Group (UNH) stock has remained largely at the same level since 7/31/2026 because of the following key factors:
1. Deterioration in 2027 Medicare Star Ratings.
UnitedHealth Group's stock faced pressure following the October 8, 2026, publication of the 2027 Medicare Star Ratings by the Centers for Medicare & Medicaid Services (CMS). J.P. Morgan estimated that UnitedHealth's proportion of members in plans rated four stars or higher would decline significantly from 81% to approximately 67%. This anticipated reduction in ratings is projected to result in a substantial $1.5 billion revenue headwind in 2028 due to decreased quality bonus payments, which contributed to investor concern about future financial performance.
2. Decline in Optum Health Segment Revenue.
The Optum Health segment experienced a notable decline in fiscal Q3 2026, with revenues decreasing by 10% year-over-year. This reduction, with revenues reaching $22.9 billion, was primarily attributed to the company serving fewer value-based care patients in certain markets. This operational weakness in a key growth segment raised concerns among investors regarding the company's ability to maintain its growth trajectory.
3. Persistent Concerns Regarding Medical Cost Trends.
Despite an improvement in the consolidated medical care ratio (MCR) to 88.4% in fiscal Q3 2026 from 89.9% a year earlier, management cautioned that medical expenses remained elevated compared to historical levels. The company also highlighted its awareness of continued elevated utilization trends, particularly in risk-based businesses, which typically see an increase in the latter half of the year. This ongoing apprehension about rising healthcare utilization and its potential impact on future profitability likely contributed to investor caution, preventing a stronger stock recovery despite the positive Q3 earnings beat.
Show less
Stock Movement Drivers
Fundamental Drivers
The -0.6% change in UNH stock from 7/31/2026 to 11/4/2026 was primarily driven by a -25.5% change in the company's P/E Multiple.| (LTM values as of) | 7312026 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 411.86 | 409.38 | -0.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 449,713 | 449,662 | 0.0% |
| Net Income Margin (%) | 2.7% | 3.5% | 31.9% |
| P/E Multiple | 31.1 | 23.1 | -25.5% |
| Shares Outstanding (Mil) | 908 | 897 | 1.2% |
| Cumulative Contribution | -0.6% |
Market Drivers
7/31/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| UNH | -0.6% | |
| Market (SPY) | 2.6% | 2.7% |
| Sector (XLV) | 16.7% | 47.2% |
Fundamental Drivers
The 11.8% change in UNH stock from 4/30/2026 to 11/4/2026 was primarily driven by a 31.1% change in the company's Net Income Margin (%).| (LTM values as of) | 4302026 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 366.12 | 409.38 | 11.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 447,567 | 449,662 | 0.5% |
| Net Income Margin (%) | 2.7% | 3.5% | 31.1% |
| P/E Multiple | 27.6 | 23.1 | -16.2% |
| Shares Outstanding (Mil) | 908 | 897 | 1.2% |
| Cumulative Contribution | 11.8% |
Market Drivers
4/30/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| UNH | 11.8% | |
| Market (SPY) | 7.0% | 2.8% |
| Sector (XLV) | 30.5% | 50.7% |
Fundamental Drivers
The 23.0% change in UNH stock from 10/31/2025 to 11/4/2026 was primarily driven by a 34.9% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 332.70 | 409.38 | 23.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 435,159 | 449,662 | 3.3% |
| Net Income Margin (%) | 4.0% | 3.5% | -12.6% |
| P/E Multiple | 17.1 | 23.1 | 34.9% |
| Shares Outstanding (Mil) | 906 | 897 | 1.0% |
| Cumulative Contribution | 23.0% |
Market Drivers
10/31/2025 to 11/4/2026| Return | Correlation | |
|---|---|---|
| UNH | 23.0% | |
| Market (SPY) | 13.4% | 12.0% |
| Sector (XLV) | 33.2% | 38.8% |
Fundamental Drivers
The -18.6% change in UNH stock from 10/31/2023 to 11/4/2026 was primarily driven by a -41.7% change in the company's Net Income Margin (%).| (LTM values as of) | 10312023 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 502.94 | 409.38 | -18.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 348,515 | 449,662 | 29.0% |
| Net Income Margin (%) | 6.1% | 3.5% | -41.7% |
| P/E Multiple | 22.2 | 23.1 | 4.3% |
| Shares Outstanding (Mil) | 930 | 897 | 3.7% |
| Cumulative Contribution | -18.6% |
Market Drivers
10/31/2023 to 11/4/2026| Return | Correlation | |
|---|---|---|
| UNH | -18.6% | |
| Market (SPY) | 89.7% | 10.4% |
| Sector (XLV) | 59.5% | 40.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| UNH Return | 45% | 7% | 1% | -2% | -33% | 26% | 29% |
| Peers Return | 33% | 12% | -9% | -26% | 11% | 38% | 53% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| UNH Win Rate | 58% | 42% | 42% | 50% | 50% | 55% | |
| Peers Win Rate | 52% | 60% | 42% | 45% | 58% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| UNH Max Drawdown | -11% | -17% | -15% | -22% | -60% | -27% | |
| Peers Max Drawdown | -18% | -19% | -24% | -37% | -34% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CVS, CI, ELV, HUM, CNC. See UNH Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/4/2026 (YTD)
How Low Can It Go
| Event | UNH | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -35.9% | -33.7% |
| % Gain to Breakeven | 56.0% | 50.9% |
| Time to Breakeven | 67 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -13.7% | -19.2% |
| % Gain to Breakeven | 15.9% | 23.8% |
| Time to Breakeven | 37 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -11.2% | -12.2% |
| % Gain to Breakeven | 12.6% | 13.9% |
| Time to Breakeven | 27 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -20.7% | -17.9% |
| % Gain to Breakeven | 26.0% | 21.8% |
| Time to Breakeven | 148 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -72.3% | -53.4% |
| % Gain to Breakeven | 261.3% | 114.4% |
| Time to Breakeven | 1225 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -12.7% | -8.6% |
| % Gain to Breakeven | 14.6% | 9.5% |
| Time to Breakeven | 96 days | 47 days |
In The Past
UnitedHealth Group's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | UNH | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -35.9% | -33.7% |
| % Gain to Breakeven | 56.0% | 50.9% |
| Time to Breakeven | 67 days | 140 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -20.7% | -17.9% |
| % Gain to Breakeven | 26.0% | 21.8% |
| Time to Breakeven | 148 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -72.3% | -53.4% |
| % Gain to Breakeven | 261.3% | 114.4% |
| Time to Breakeven | 1225 days | 1085 days |
In The Past
UnitedHealth Group's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About UnitedHealth Group (UNH)
UnitedHealth Group (UNH) is a comprehensive and diversified healthcare company operating across multiple segments of the United States healthcare system. A significant portion of its business is through UnitedHealthcare, which offers a wide array of health benefit plans and services. These plans cater to various customers including national, public sector, mid-sized, and small employers, as well as individuals. This segment also manages specialized health coverage for seniors through Medicare plans and participates in government programs like Medicaid and children's health insurance. Complementing this, OptumHealth focuses on direct care delivery, health management services, and connecting individuals to extensive networks of care providers.
Beyond traditional insurance and direct patient care, UNH provides essential support and technology services to the broader healthcare industry. Its OptumInsight segment delivers software products, information services, advisory consulting, and managed services outsourcing contracts. These offerings assist a diverse clientele including hospital systems, physicians, other health plans, governments, and life sciences companies in optimizing their operations and improving outcomes. Furthermore, the OptumRx segment functions as a major pharmacy care services provider, handling everything from retail network contracting and home delivery to specialty pharmacy services and developing clinical programs for drug adherence and formulary management.
In summary, UnitedHealth Group serves a vast and varied customer base spanning the entire healthcare ecosystem. Its primary customers include individual consumers seeking health coverage or direct care, employers of all sizes providing health benefits, and government entities sponsoring health programs for various populations. The company also acts as a critical partner for healthcare organizations such as hospitals, physician groups, and other health plans, along with life sciences companies, by offering advanced technology, consulting expertise, and pharmacy benefit management solutions, thereby playing a multifaceted role in the administration and delivery of healthcare.
```AI Analysis | Feedback
Here are 1-2 brief analogies to describe UnitedHealth Group (UNH):
- It's like the Microsoft of healthcare, providing a vast ecosystem of health plans, technology, and services across the industry.
- Think of it as the J.P. Morgan Chase of healthcare, a diversified giant offering everything from insurance and pharmacy benefits to direct care and IT solutions.
AI Analysis | Feedback
Major Products and Services of UnitedHealth Group (UNH)
- Health Benefit Plans and Services: Offers a wide array of health and dental insurance plans and services for individuals, employers, and government-sponsored programs like Medicare and Medicaid.
- Healthcare Delivery and Management: Provides direct patient care through its care delivery systems and networks, alongside health management, consumer engagement, and financial services.
- Pharmacy Benefit Management (PBM): Delivers comprehensive pharmacy care services, including retail network contracting, home delivery, specialty pharmacy, and drug therapy management programs.
- Healthcare Technology, Consulting, and Outsourcing: Offers software and information products, advisory consulting, and managed services outsourcing to hospitals, health plans, and other healthcare organizations.
AI Analysis | Feedback
UnitedHealth Group (UNH) serves a diverse range of customers, encompassing both individuals and various types of organizations and government entities. Based on the company description, its major customer categories are:
- Employers and Government Entities: UnitedHealth Group provides health benefit plans and services to national employers, public sector employers, mid-sized employers, and small businesses. It also serves government entities through Medicaid plans, children's health insurance programs, and as a provider of health management services and technology solutions. The OptumRx segment also primarily serves employers and health plans through its pharmacy care services.
- Healthcare Providers and Other Organizations: Through its OptumInsight segment, the company offers software, information products, advisory consulting, and managed services to hospital systems, physicians, other health plans, governments, and life sciences companies.
- Individuals: The company directly serves individuals with consumer-oriented health benefit plans, including those aged 50 and older, as well as individuals enrolled in Medicaid and children's health insurance programs. OptumHealth also directly provides care delivery and health management services to individuals.
AI Analysis | Feedback
AI Analysis | Feedback
Stephen J. Hemsley, Chief Executive Officer
Stephen J. Hemsley assumed the role of Chief Executive Officer in May 2025, succeeding Sir Andrew Witty. He previously served as Chairman and former CEO of UnitedHealth Group.
Wayne S. DeVeydt, Chief Financial Officer
Wayne S. DeVeydt was appointed Chief Financial Officer, effective September 2, 2025. Prior to this role, he was a managing director and operating partner at Bain Capital, a private equity firm. From 2018 to 2020, he served as chairman and CEO of Surgery Partners, Inc. He also held the position of Chief Financial Officer at Anthem, Inc. (now Elevance) from 2007 to 2016, and was a partner with PricewaterhouseCoopers LLP, focusing on the health care sector.
John Rex, President
John Rex became President of UnitedHealth Group on April 1, 2024, after previously serving as the company's Executive Vice President and Chief Financial Officer since 2016. He joined UnitedHealth Group in 2012 as the Chief Financial Officer and Executive Vice President of Optum, Inc., a UnitedHealth Group subsidiary. Before joining Optum, Mr. Rex was a leading equity research analyst and managing director at J.P. Morgan, and also served as a Senior Research Analyst at Bear, Stearns & Co., Inc. He also held the position of CFO and Executive Vice President for InGensa, Inc., and worked as a strategy and operations consultant specializing in health services. He is a certified public accountant and advised clients for Ernst & Young in the health services sector.
Rupert Bondy, Executive Vice President and Chief Legal Officer
Rupert Bondy joined UnitedHealth Group in March 2022 as Executive Vice President and Chief Legal Officer. Before joining UnitedHealth Group, he served as senior vice president, general counsel, and corporate secretary for Reckitt, a consumer goods group.
Patrick Conway, M.D., CEO, Optum
Dr. Patrick Conway was named CEO of Optum in 2025. He joined Optum in 2020 and previously served as the CEO of Care Solutions. Prior to his time at Optum, Dr. Conway was the president and CEO of Blue Cross and Blue Shield of North Carolina.
AI Analysis | Feedback
The key risks to UnitedHealth Group (UNH) primarily revolve around regulatory scrutiny, the aftermath of significant cybersecurity incidents, and challenges within its Medicare Advantage business.
-
Regulatory Scrutiny and Antitrust Investigations: UnitedHealth Group is facing extensive scrutiny and ongoing antitrust investigations by the Department of Justice (DOJ) into its business practices, particularly concerning the relationship between its UnitedHealthcare insurance arm and its Optum health services segments. These investigations encompass allegations of anticompetitive behavior, upcoding, overbilling, and denying patient care. The DOJ has also examined UnitedHealth's acquisitions of physician practices and its billing practices within Medicare Advantage and Optum Rx. The potential consequences include legal challenges, increased operational expenses due to compliance requirements, and possible divestiture of Optum assets.
-
Cybersecurity Risks and Data Breaches: A significant risk stems from the potential for and fallout from major cybersecurity incidents. The February 2024 cyberattack on Change Healthcare, a subsidiary within UnitedHealth's Optum Insight segment, exposed the sensitive data of nearly 200 million people, making it the largest healthcare data breach in U.S. history. This incident alone incurred billions of dollars in financial costs for UnitedHealth Group and led to widespread disruptions in claims processing. The company also experienced another breach through its Episource subsidiary in 2025, affecting millions more. These events highlight substantial vulnerabilities in its IT infrastructure and expose the company to ongoing lawsuits and reputational damage.
-
Medicare Advantage Business Challenges: UnitedHealth Group's significant presence in the Medicare Advantage (MA) market faces several specific risks. These include ongoing regulatory investigations into billing practices, with allegations of inflating patient risk scores to secure higher payments. Furthermore, the company is susceptible to potential downgrades in its Medicare Star Ratings for 2027, which could negatively impact quality bonus payments and reduce the competitiveness of its plans. Elevated medical costs within the Medicare Advantage segment also pose a challenge, potentially affecting profitability.
AI Analysis | Feedback
- Disruptive competition from tech giants expanding into healthcare services. Amazon's continued expansion in pharmacy (e.g., Amazon Pharmacy, PillPack) and primary care (e.g., One Medical) poses a direct competitive threat to UnitedHealth Group's OptumRx segment (pharmacy care services and home delivery) and OptumHealth segment (care delivery systems). Amazon leverages its logistics, pricing power, and direct-to-consumer model, which could significantly challenge OptumRx's market share and profitability by offering alternative, often more convenient and transparent, services.
- Increasing legislative and regulatory scrutiny of Pharmacy Benefit Managers (PBMs). There is growing bipartisan political pressure and ongoing legislative efforts at both federal and state levels to increase transparency, regulate PBM practices, and potentially limit their profitability or vertical integration. This directly threatens the business model and financial performance of UnitedHealth Group's OptumRx segment by potentially forcing changes in its operations, rebate structures, and revenue streams.
AI Analysis | Feedback
UnitedHealth Group operates within several large and growing addressable markets in the United States for its diverse healthcare products and services. The company's main segments target distinct areas of the healthcare industry.
UnitedHealthcare
UnitedHealthcare, which offers health benefit plans and services, operates within the broader U.S. healthcare market. The U.S. healthcare market was valued at approximately USD 4.87 trillion in 2025 and is estimated to reach USD 5.15 trillion in 2026. This market is projected to expand to USD 8.09 trillion by 2034, growing at a compound annual growth rate (CAGR) of 5.80% from 2026 to 2034. National health expenditures in the U.S. reached USD 5.3 trillion in 2024.
Optum
The U.S. addressable market for all Optum services, encompassing data and analytics, care delivery, population health management and engagement, health financial services, health IT, benefit and care operations, and pharmacy care services, is estimated at more than USD 850 billion. This market is expected to grow at a mid-single digit annual percentage rate over the next several years.
OptumHealth
OptumHealth provides care provider networks, health management services, and direct care delivery. The U.S. integrated delivery network market, which includes unified and vertically integrated healthcare systems, was valued at USD 1,588.15 billion in 2025 and is poised to grow from USD 1,751.73 billion in 2026 to USD 4,232.98 billion by 2035, at a CAGR of 10.3%. Additionally, the U.S. care services market was valued at USD 456.6 billion in 2021, reached USD 478.1 billion in 2022, and is projected to grow to USD 748.5 billion by 2030. The U.S. home healthcare market, a component of care delivery, was estimated at USD 155.45 billion in 2025 and is expected to surpass USD 320.69 billion by 2035.
OptumInsight
OptumInsight offers software and information products, advisory consulting, and managed services outsourcing. The markets OptumInsight serves, including payers, care providers, state governments, and life sciences, represent more than USD 300 billion in market opportunity. More specifically, the U.S. healthcare IT market is valued at USD 213.50 billion in 2026 and is projected to reach USD 414.34 billion by 2031. The U.S. healthcare IT software market size was valued at USD 189.6 billion in 2025 and is projected to grow to USD 634.0 billion by 2033. For healthcare consulting, the U.S. market size is approximately USD 21.9 billion in 2026.
OptumRx
OptumRx provides pharmacy care services and programs. The U.S. pharmacy benefit management (PBM) market size is estimated at USD 504.08 billion in 2026 and is expected to reach around USD 1,120.83 billion by 2035, expanding at a CAGR of 9.7% from 2026 to 2035. Another estimate places the U.S. PBM market size at USD 628.2 billion in 2026.
AI Analysis | Feedback
UnitedHealth Group (UNH) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
-
Expansion in Value-Based Care within Optum Health: Optum Health anticipates growth by increasing the scope and types of care services offered, particularly in home-based care and for individuals with complex health needs. This segment is accelerating its focus on value-based care models, with management projecting sustained operating improvements and substantial earnings growth by 2027, aiming for a 6%-8% margin range by 2028. Key initiatives include expanding fully accountable patient relationships and enhancing high-performing service lines such as home health and surgical centers.
-
Growth in Optum Rx Pharmacy Care Services and Specialty Pharmacy: Revenue for Optum Rx is expected to be driven by its pharmacy care offerings, attracting new customers to its pharmacy benefits management services, and expanding its specialty services, including the adoption of biosimilars. The company has diversified its customer base, with over 50% of Optum Rx's membership now coming from external clients. This segment projects a long-term average annual revenue growth rate of 5% to 8%.
-
UnitedHealthcare Membership Growth Across Segments: UnitedHealthcare aims to grow revenue by increasing its membership base. This includes adding new consumers in the domestic commercial business, expanding its reach in Medicare Advantage by focusing on disciplined benefit design and high-value plan offerings, and increasing services for individuals with complex needs in Medicaid, anticipating margin recovery after 2026.
-
Strategic Investments in AI and Technology for Operational Efficiency and New Offerings: UnitedHealth Group is heavily investing in artificial intelligence and other advanced technologies to modernize its operations. These initiatives are designed to reduce administrative complexities, enhance patient and clinician experiences, and improve the efficiency of care delivery. Optum Insight, in particular, is integrating AI into existing products and developing new AI-first platforms, expecting significant progress in 2027 that will lay the groundwork for accelerated growth in subsequent years.
AI Analysis | Feedback
Share Repurchases
- UnitedHealth Group expects to make at least $5 billion in share repurchases in 2026, having already spent $4 billion through mid-July 2026.
- In June 2024, the Board of Directors authorized the repurchase of up to 35 million shares of common stock, in addition to previously authorized amounts, with no expiration date.
- Annual share repurchases were $5.545 billion in 2025, $9 billion in 2024, and $8 billion in 2023.
Share Issuance
- The company's shares outstanding at the end of fiscal 2025 were 911.0 million, unchanged from fiscal 2024.
- As of June 30, 2026, shares outstanding were 906.0 million, representing a general decline over the past few years.
Outbound Investments
- In 2022, UnitedHealth Group completed the acquisition of Change Healthcare for approximately $8 billion, after initial regulatory challenges.
- The acquisition of LHC Group for $5.4 billion was agreed upon in 2022 and closed in February 2023.
- UnitedHealth announced the acquisition of Amedisys in 2023 for $3.3 billion, which faced a U.S. Department of Justice lawsuit in November 2024 on antitrust grounds.
Capital Expenditures
- UnitedHealth Group's capital expenditures were $3.622 billion in 2025, $3.499 billion in 2024, $3.386 billion in 2023, $2.802 billion in 2022, and $2.454 billion in 2021.
- Estimated capital expenditures for 2026 are $3.8 billion. The forecast for the next fiscal year is $3.7 billion, with an expected average of $4.064 billion over the next five fiscal years.
- The company plans to invest $3 billion in artificial intelligence in 2026 and 2027 to enhance efficiency, having already seen significant reductions in manual contact costs and improvements in claims processing through AI.
Peer Outperformance in Managed Health Care
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 13.4% | 63.7% | 103.3% | CAH 490% · MCK 391% · COR 194% |
| Health Care Services | 20 | 44.0% | 33.3% | 11.6% | HIMS 220% · RDNT 148% · DGX 96% |
| Managed Health Care ← | 8 | 44.6% | 5.6% | 0.6% | OSCR 107% · HQY 59% · ELV 11% |
| Health Care Facilities | 25 | 16.9% | 18.4% | -3.0% | THC 302% · NHC 241% · EHC 202% |
| Health Care Equipment | 50 | 14.4% | 18.7% | -15.0% | UFPT 408% · GKOS 348% · PLSE 147% |
| Pharmaceuticals | 60 | -5.1% | 8.2% | -35.2% | LQDA 999% · KNSA 546% · LLY 448% |
| Health Care Supplies | 11 | 34.9% | 23.0% | -36.1% | LNTH 267% · HAE 76% · MMSI 33% |
| Life Sciences Tools & Services | 108 | -6.2% | -10.3% | -74.1% | AXGN 288% · NTRA 253% · MEDP 189% |
| Biotechnology | 364 | -21.1% | -31.5% | -81.7% | ELVN 1112% · TRVI 1046% · DNTH 930% |
| Health Care Technology | 21 | -23.4% | -56.5% | -82.3% | VEEV -3% · DOCS -52% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 358.92 |
| Mkt Cap | 87.3 |
| Rev LTM | 242,616 |
| Op Inc LTM | 11,986 |
| FCF LTM | 7,814 |
| FCF 3Y Avg | 5,362 |
| CFO LTM | 8,936 |
| CFO 3Y Avg | 6,601 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.2% |
| Rev Chg 3Y Avg | 9.3% |
| Rev Chg Q | 3.6% |
| QoQ Delta Rev Chg LTM | 0.9% |
| Op Inc Chg LTM | 23.8% |
| Op Inc Chg 3Y Avg | -2.2% |
| Op Mgn LTM | 3.4% |
| Op Mgn 3Y Avg | 3.2% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 3.7% |
| CFO/Rev 3Y Avg | 2.6% |
| FCF/Rev LTM | 3.2% |
| FCF/Rev 3Y Avg | 1.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 87.3 |
| P/S | 0.3 |
| P/Op Inc | 12.2 |
| P/EBIT | 13.5 |
| P/E | 20.8 |
| P/CFO | 10.2 |
| Total Yield | 6.8% |
| Dividend Yield | 1.8% |
| FCF Yield 3Y Avg | 6.3% |
| D/E | 0.4 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 9.4% |
| 3M Rtn | 12.6% |
| 6M Rtn | 15.2% |
| 12M Rtn | 33.8% |
| 3Y Rtn | 2.9% |
| 1M Excs Rtn | 12.2% |
| 3M Excs Rtn | 13.4% |
| 6M Excs Rtn | 12.4% |
| 12M Excs Rtn | 23.5% |
| 3Y Excs Rtn | -77.7% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| UnitedHealthcare | 344,903 | 298,208 | 281,360 | 249,741 | 222,899 |
| Optum Rx | 154,726 | 133,231 | 116,087 | 99,773 | 91,314 |
| Optum Health | 101,957 | 105,358 | 95,319 | 71,174 | 54,065 |
| Optum Insight | 19,417 | 18,757 | 18,932 | 14,581 | 12,199 |
| Optum Eliminations | -5,480 | -4,389 | -3,703 | -2,760 | -2,013 |
| Corporate and Eliminations | -167,956 | -150,887 | -136,373 | -108,347 | -90,867 |
| Total | 447,567 | 400,278 | 371,622 | 324,162 | 287,597 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| UnitedHealthcare | 9,425 | 15,584 | 16,415 | 14,379 | 11,975 |
| Optum Rx | 7,193 | 5,836 | 5,115 | 4,436 | 4,135 |
| Optum Insight | 2,624 | 3,097 | 4,268 | 3,588 | 3,398 |
| Corporate and Eliminations | 0 | 0 | 0 | 0 | 0 |
| Optum Eliminations | 0 | 0 | 0 | 0 | 0 |
| Optum Health | -278 | 7,770 | 6,560 | 6,032 | 4,462 |
| Total | 18,964 | 32,287 | 32,358 | 28,435 | 23,970 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| UnitedHealthcare | 124,051 | 119,009 | 110,943 | 107,094 | 102,967 |
| Optum Health | 100,991 | 96,472 | 89,432 | 68,950 | 60,474 |
| Optum Rx | 62,262 | 59,086 | 51,266 | 47,476 | 40,181 |
| Optum Insight | 35,400 | 34,452 | 34,173 | 31,090 | 16,868 |
| Optum Eliminations | 0 | 0 | 0 | 0 | 0 |
| Corporate and Eliminations | -13,123 | -10,741 | -12,094 | -8,905 | -8,284 |
| Total | 309,581 | 298,278 | 273,720 | 245,705 | 212,206 |
Price Behavior
| Market Price | $409.38 | |
| Market Cap ($ Bil) | 367.2 | |
| First Trading Date | 03/26/1990 | |
| Distance from 52W High | -5.6% | |
| 50 Days | 200 Days | |
| DMA Price | $390.19 | $360.74 |
| DMA Trend | down | up |
| Distance from DMA | 4.9% | 13.5% |
| 3M | 1YR | |
| Volatility | 23.0% | 34.5% |
| Downside Capture | 38.98 | 27.25 |
| Upside Capture | 48.41 | 50.13 |
| Correlation (S&P 500) | 5.5% | 12.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.12 | 0.06 | -0.04 | 0.02 | 0.31 | 0.25 |
| Up Beta | -0.86 | -1.03 | -0.99 | -0.63 | 0.02 | 0.38 |
| Down Beta | -0.63 | -0.84 | -0.59 | 0.18 | 0.41 | 0.20 |
| Up Capture | 148% | 68% | 28% | 23% | 35% | 2% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 9 | 19 | 28 | 57 | 118 | 380 |
| Down Capture | -26% | 24% | 41% | -0% | 32% | 45% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 13 | 24 | 36 | 69 | 133 | 372 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with UNH | |
|---|---|---|---|---|
| UNH | 26.0% | 34.5% | 0.72 | - |
| Sector ETF (XLV) | 33.1% | 16.7% | 1.53 | 38.9% |
| Equity (SPY) | 13.2% | 12.9% | 0.68 | 12.1% |
| Gold (GLD) | 1.0% | 28.8% | 0.03 | 8.1% |
| Commodities (DBC) | 35.9% | 21.2% | 1.34 | -1.6% |
| Real Estate (VNQ) | 14.3% | 14.1% | 0.70 | 17.3% |
| Bitcoin (BTCUSD) | -28.2% | 43.4% | -0.65 | 17.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with UNH | |
|---|---|---|---|---|
| UNH | -0.2% | 32.1% | 0.04 | - |
| Sector ETF (XLV) | 9.3% | 15.3% | 0.40 | 47.7% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | 21.2% |
| Gold (GLD) | 17.3% | 19.1% | 0.73 | 3.9% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | 1.1% |
| Real Estate (VNQ) | 1.8% | 18.9% | -0.01 | 19.1% |
| Bitcoin (BTCUSD) | 5.5% | 51.5% | 0.29 | 10.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with UNH | |
|---|---|---|---|---|
| UNH | 12.9% | 30.3% | 0.46 | - |
| Sector ETF (XLV) | 12.5% | 16.8% | 0.61 | 61.8% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 44.3% |
| Gold (GLD) | 11.9% | 16.5% | 0.59 | 3.1% |
| Commodities (DBC) | 7.4% | 18.1% | 0.33 | 11.3% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | 37.6% |
| Bitcoin (BTCUSD) | 61.0% | 66.2% | 1.01 | 10.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 10/22/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/13/2026 | -0.2% | 7.5% | |
| 7/16/2026 | 1.2% | 3.1% | -4.6% |
| 4/21/2026 | 7.0% | 9.6% | 20.3% |
| 1/27/2026 | 4.0% | 0.5% | 1.4% |
| 10/28/2025 | 0.5% | -8.8% | -10.8% |
| 7/29/2025 | -7.5% | -14.6% | 6.5% |
| 4/17/2025 | -22.4% | -27.5% | -50.1% |
| 1/16/2025 | -0.2% | 4.3% | -1.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 15 | 14 | 15 |
| # Negative | 10 | 11 | 9 |
| Median Positive | 3.8% | 5.2% | 6.5% |
| Median Negative | -1.8% | -5.1% | -6.7% |
| Max Positive | 7.2% | 12.6% | 20.3% |
| Max Negative | -22.4% | -27.5% | -50.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/13/2026 | -0.2% | 7.5% | |
| 7/16/2026 | 1.2% | 3.1% | -4.6% |
| 4/21/2026 | 7.0% | 9.6% | 20.3% |
| 1/27/2026 | 4.0% | 0.5% | 1.4% |
| 10/28/2025 | 0.5% | -8.8% | -10.8% |
| 7/29/2025 | -7.5% | -14.6% | 6.5% |
| 4/17/2025 | -22.4% | -27.5% | -50.1% |
| 1/16/2025 | -0.2% | 4.3% | -1.9% |
| 10/15/2024 | -8.1% | -5.6% | 1.5% |
| 7/16/2024 | 6.5% | 8.4% | 11.4% |
| 4/16/2024 | 5.2% | 10.2% | 15.3% |
| 1/12/2024 | -0.5% | -1.6% | -0.9% |
| 10/13/2023 | 2.6% | 1.2% | 3.0% |
| 7/14/2023 | 7.2% | 12.6% | 13.5% |
| 4/14/2023 | -2.7% | -7.4% | -6.7% |
| 1/13/2023 | -0.9% | -0.8% | 0.7% |
| 10/14/2022 | 0.6% | 2.2% | 2.4% |
| 7/15/2022 | 5.4% | 4.0% | 8.2% |
| 4/14/2022 | -0.4% | 0.1% | -9.6% |
| 1/19/2022 | 0.1% | -0.9% | 1.7% |
| 10/14/2021 | 4.2% | 7.8% | 13.3% |
| 7/15/2021 | 1.3% | -0.0% | -2.1% |
| 4/15/2021 | 3.8% | 6.2% | 8.8% |
| 1/20/2021 | 1.2% | -5.1% | -7.5% |
| 10/14/2020 | -2.9% | -2.4% | 6.1% |
| SUMMARY STATS | |||
| # Positive | 15 | 14 | 15 |
| # Negative | 10 | 11 | 9 |
| Median Positive | 3.8% | 5.2% | 6.5% |
| Median Negative | -1.8% | -5.1% | -6.7% |
| Max Positive | 7.2% | 12.6% | 20.3% |
| Max Negative | -22.4% | -27.5% | -50.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/03/2026 | 10-Q |
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/02/2026 | 10-K |
| 09/30/2025 | 10/28/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/03/2026 | 10-Q |
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/02/2026 | 10-K |
| 09/30/2025 | 10/28/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/15/2022 | 10-K |
| 09/30/2021 | 11/03/2021 | 10-Q |
| 06/30/2021 | 08/03/2021 | 10-Q |
| 03/31/2021 | 05/05/2021 | 10-Q |
| 12/31/2020 | 03/01/2021 | 10-K |
| 09/30/2020 | 11/02/2020 | 10-Q |
| 06/30/2020 | 08/03/2020 | 10-Q |
| 03/31/2020 | 05/06/2020 | 10-Q |
| 12/31/2019 | 02/14/2020 | 10-K |
Recent Forward Guidance
Updated 10/14/2026Latest: Q3 2026 Earnings Reported 10/13/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Earnings Attributable to UnitedHealth Group Common Shareholders | Reported | 17.65 Bil | 17.65 Bil | |||||
| 2026 Adjusted Net Earnings Attributable to UnitedHealth Group Common Shareholders | Reported | 18.59 Bil | 18.59 Bil | |||||
| 2026 Debt-to-Capital Ratio | Reported | 0.4 | ||||||
| 2026 Diluted Earnings Per Share | Reported | 19.5 | 19.5 | 4.3% | Raised | Guidance: 18.7 for 2026 | ||
| 2026 Adjusted Diluted Earnings Per Share | Reported | 20.5 | 20.5 | 3.8% | Raised | Guidance: 19.75 for 2026 | ||
Prior: Q2 2026 Earnings Reported 7/16/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 UnitedHealthcare Reported Operating Earnings | Reported | 12.00 Bil | ||||||
| 2026 Optum Health Reported Operating Earnings | Reported | 2.27 Bil | ||||||
| 2026 Optum Insight Reported Operating Earnings | Reported | 4.92 Bil | ||||||
| 2026 Optum Rx Reported Operating Earnings | Reported | 6.25 Bil | ||||||
| 2026 UnitedHealth Group Reported Operating Earnings | Reported | 25.45 Bil | ||||||
| 2026 Medical Care Ratio | Reported | 0.88 | ||||||
| 2026 Cash Flows from Operations | Reported | 24.00 Bil | ||||||
| 2026 Adjusted Net Earnings per Share | Reported | 19.5 | 19.75 | 20 | 8.2% | Raised | Guidance: 18.25 for 2026 | |
| 2026 Diluted Net Earnings per Share | Reported | 18.45 | 18.7 | 18.95 | ||||
| 2026 Share Repurchase | Reported | 5.00 Bil | ||||||
Q1 2026 Earnings Reported 4/21/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Share Repurchases | Reported | 2.00 Bil | ||||||
| 2026 Debt-to-Capital Ratio | Reported | 0.4 | ||||||
| 2026 Adjusted EPS | Reported | 18.25 | 2.8% | Raised | Guidance: 17.75 for 2026 | |||
Q4 2025 Earnings Reported 1/27/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Earnings from Operations | Reported | 24.00 Bil | ||||||
| 2026 Cash Flows from Operations | Reported | 18.00 Bil | ||||||
| 2026 Revenue | Reported | 439.00 Bil | ||||||
| 2026 Operating Margin | Reported | 5.5% | ||||||
| 2026 Adjusted Earnings per Share | Reported | 17.75 | 9.2% | Higher New | Guidance: 16.25 for 2025 | |||
Insider Activity
Updated 9/24/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Conway, Patrick Hugh | Chief Executive Officer, Optum | Direct | Sell | 8252026 | 390.00 | 1,169 | 455,910 | 5,977,841 | Form |
| 2 | Conway, Patrick Hugh | Chief Executive Officer, Optum | Direct | Sell | 8072026 | 410.00 | 500 | 205,000 | 6,763,687 | Form |
| 3 | Conway, Patrick Hugh | Chief Executive Officer, Optum | Direct | Sell | 4272026 | 355.00 | 800 | 284,000 | 6,320,772 | Form |
| 4 | Baker, Charles D | Trust | Sell | 9152025 | 356.05 | 27 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Conway, Patrick Hugh | Chief Executive Officer, Optum | Direct | Sell | 8252026 | 390.00 | 1,169 | 455,910 | 5,977,841 | Form |
| 2 | Conway, Patrick Hugh | Chief Executive Officer, Optum | Direct | Sell | 8072026 | 410.00 | 500 | 205,000 | 6,763,687 | Form |
| 3 | Conway, Patrick Hugh | Chief Executive Officer, Optum | Direct | Sell | 4272026 | 355.00 | 800 | 284,000 | 6,320,772 | Form |
| 4 | Baker, Charles D | Trust | Sell | 9152025 | 356.05 | 27 | Form |
Investor Activity (13F)
Updated Nov 5, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Naya Capital Management UK LTD | $273.4 Mil | 23.2% | 4 | ADD +10.7% | 13F |
| Solel Partners LP | $55.9 Mil | 11.9% | 19 | Hold | 13F |
| Marshfield Associates | $511.6 Mil | 10.2% | 17 | ADD +14.0% | 13F |
| Seilern Investment Management Ltd | $76.1 Mil | 9.1% | 24 | TRIM -21.0% | 13F |
| Warther Private Wealth, LLC | $31.9 Mil | 7.5% | 40 | ADD +5.7% | 13F |
| GUARDCAP ASSET MANAGEMENT Ltd | $126.8 Mil | 7.3% | 27 | TRIM -43.9% | 13F |
| Boone Capital Management LLC | $21.4 Mil | 6.6% | 13 | ADD +28.3% | 13F |
| Vulcan Value Partners, LLC | $247.0 Mil | 6.5% | 33 | TRIM -15.7% | 13F |
| Route One Investment Company, L.P. | $144.2 Mil | 6.3% | 18 | ADD +5.0% | 13F |
| Gobi Capital LLC | $104.5 Mil | 6.1% | 10 | TRIM -5.2% | 13F |
| MFF Capital Investments Ltd | $84.5 Mil | 5.6% | 19 | ADD +11.8% | 13F |
| Bowie Capital Management, LLC | $96.2 Mil | 4.6% | 29 | ADD +27.6% | 13F |
| Patient Capital Management, LLC | $118.3 Mil | 4.4% | 38 | ADD +18.7% | 13F |
| Generali Powszechne Towarzystwo Emerytalne | $24.4 Mil | 4.3% | 28 | Hold | 13F |
| Focused Investors LLC | $132.5 Mil | 4.3% | 22 | Hold | 13F |
| Longview Partners (Guernsey) LTD | $303.5 Mil | 4.3% | 25 | TRIM -10.6% | 13F |
| One Fin Capital Management LP | $8.9 Mil | 3.4% | 19 | New | 13F |
| AltraVue Capital, LLC | $38.3 Mil | 3.3% | 49 | ADD +80.6% | 13F |
| Ruane, Cunniff & Goldfarb L.P. | $197.1 Mil | 3.3% | 50 | Hold | 13F |
| TB Alternative Assets Ltd. | $12.8 Mil | 2.7% | 36 | New | 13F |
| Sector Gamma AS | $9.9 Mil | 2.3% | 42 | New | 13F |
| Concord Investment Counsel Inc. | $6.5 Mil | 2.2% | 41 | Hold | 13F |
| PARUS FINANCE (UK) Ltd | $7.3 Mil | 2.2% | 37 | Hold | 13F |
| Smead Capital Management, Inc. | $93.9 Mil | 2.0% | 32 | ADD +12.4% | 13F |
| BloombergSen Inc. | $18.2 Mil | 2.0% | 27 | Hold | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| H&H International Investment, LLC | $162.7 Mil | 0.8% | 19 | New | 13F |
| Unisphere Establishment | $108.2 Mil | 0.9% | 50 | New | 13F |
| Maple Rock Capital Partners Inc. | $58.3 Mil | 1.9% | 44 | New | 13F |
| Crake Asset Management LLP | $41.4 Mil | 1.4% | 20 | New | 13F |
| Spear Holdings RSC Ltd | $14.3 Mil | 1.5% | 17 | New | 13F |
| PBCay One RSC Ltd | $14.3 Mil | 1.5% | 17 | New | 13F |
| TB Alternative Assets Ltd. | $12.8 Mil | 2.7% | 36 | New | 13F |
| Sector Gamma AS | $9.9 Mil | 2.3% | 42 | New | 13F |
| One Fin Capital Management LP | $8.9 Mil | 3.4% | 19 | New | 13F |
| Cincinnati Specialty Underwriters Insurance CO | $7.0 Mil | 1.7% | 46 | New | 13F |
| AltraVue Capital, LLC | $38.3 Mil | 3.3% | 49 | ADD +80.6% | 13F |
| Boone Capital Management LLC | $21.4 Mil | 6.6% | 13 | ADD +28.3% | 13F |
| Bowie Capital Management, LLC | $96.2 Mil | 4.6% | 29 | ADD +27.6% | 13F |
| Patient Capital Management, LLC | $118.3 Mil | 4.4% | 38 | ADD +18.7% | 13F |
| Marshfield Associates | $511.6 Mil | 10.2% | 17 | ADD +14.0% | 13F |
| Smead Capital Management, Inc. | $93.9 Mil | 2.0% | 32 | ADD +12.4% | 13F |
| MFF Capital Investments Ltd | $84.5 Mil | 5.6% | 19 | ADD +11.8% | 13F |
| Naya Capital Management UK LTD | $273.4 Mil | 23.2% | 4 | ADD +10.7% | 13F |
| Kinsale Capital Group, Inc. | $9.2 Mil | 1.5% | 41 | ADD +6.8% | 13F |
| Warther Private Wealth, LLC | $31.9 Mil | 7.5% | 40 | ADD +5.7% | 13F |
| Route One Investment Company, L.P. | $144.2 Mil | 6.3% | 18 | ADD +5.0% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | As Of | Filing |
|---|---|---|---|---|---|---|
| Eminence Capital, LP | $124.9 Mil | 2.0% | 39 | Exited | Dec 31, 2025 | 13F |
| Bristol Gate Capital Partners Inc. | $80.4 Mil | 4.6% | 33 | Exited | Dec 31, 2025 | 13F |
| RK Capital Management, LLC/FL | $61.1 Mil | 3.8% | 20 | Exited | Dec 31, 2025 | 13F |
| Parsifal Capital Management, LP | $49.6 Mil | 5.0% | 15 | Exited | Dec 31, 2025 | 13F |
| Iron Triangle Partners LP | $23.1 Mil | 2.6% | 27 | Exited | Dec 31, 2025 | 13F |
| Casdin Capital, LLC | $16.5 Mil | 1.0% | 38 | Exited | Dec 31, 2025 | 13F |
| Iyo Bank, Ltd. | $7.6 Mil | 2.4% | 37 | Exited | Dec 31, 2025 | 13F |
| GUARDCAP ASSET MANAGEMENT Ltd | $126.8 Mil | 7.3% | 27 | TRIM -43.9% | Mar 31, 2026 | 13F |
| Seilern Investment Management Ltd | $76.1 Mil | 9.1% | 24 | TRIM -21.0% | Mar 31, 2026 | 13F |
| Vulcan Value Partners, LLC | $247.0 Mil | 6.5% | 33 | TRIM -15.7% | Mar 31, 2026 | 13F |
| Longview Partners (Guernsey) LTD | $303.5 Mil | 4.3% | 25 | TRIM -10.6% | Mar 31, 2026 | 13F |
| Venator Management LLC | $6.2 Mil | 1.5% | 28 | TRIM -6.8% | Mar 31, 2026 | 13F |
| Gobi Capital LLC | $104.5 Mil | 6.1% | 10 | TRIM -5.2% | Mar 31, 2026 | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Sanders Capital, LLC | $1.6 Bil | 1.9% | 44 | Hold | 13F |
| Marshfield Associates | $511.6 Mil | 10.2% | 17 | ADD +14.0% | 13F |
| Longview Partners (Guernsey) LTD | $303.5 Mil | 4.3% | 25 | TRIM -10.6% | 13F |
| Naya Capital Management UK LTD | $273.4 Mil | 23.2% | 4 | ADD +10.7% | 13F |
| Vulcan Value Partners, LLC | $247.0 Mil | 6.5% | 33 | TRIM -15.7% | 13F |
| PineStone Asset Management Inc. | $218.9 Mil | 1.5% | 44 | Hold | 13F |
| Ruane, Cunniff & Goldfarb L.P. | $197.1 Mil | 3.3% | 50 | Hold | 13F |
| H&H International Investment, LLC | $162.7 Mil | 0.8% | 19 | New | 13F |
| Route One Investment Company, L.P. | $144.2 Mil | 6.3% | 18 | ADD +5.0% | 13F |
| Focused Investors LLC | $132.5 Mil | 4.3% | 22 | Hold | 13F |
| GUARDCAP ASSET MANAGEMENT Ltd | $126.8 Mil | 7.3% | 27 | TRIM -43.9% | 13F |
| Patient Capital Management, LLC | $118.3 Mil | 4.4% | 38 | ADD +18.7% | 13F |
| Unisphere Establishment | $108.2 Mil | 0.9% | 50 | New | 13F |
| Gobi Capital LLC | $104.5 Mil | 6.1% | 10 | TRIM -5.2% | 13F |
| Bowie Capital Management, LLC | $96.2 Mil | 4.6% | 29 | ADD +27.6% | 13F |
| Smead Capital Management, Inc. | $93.9 Mil | 2.0% | 32 | ADD +12.4% | 13F |
| MFF Capital Investments Ltd | $84.5 Mil | 5.6% | 19 | ADD +11.8% | 13F |
| Seilern Investment Management Ltd | $76.1 Mil | 9.1% | 24 | TRIM -21.0% | 13F |
| Maple Rock Capital Partners Inc. | $58.3 Mil | 1.9% | 44 | New | 13F |
| Solel Partners LP | $55.9 Mil | 11.9% | 19 | Hold | 13F |
| Crake Asset Management LLP | $41.4 Mil | 1.4% | 20 | New | 13F |
| AltraVue Capital, LLC | $38.3 Mil | 3.3% | 49 | ADD +80.6% | 13F |
| Greenwoods Asset Management Hong Kong Ltd. | $35.3 Mil | 0.9% | 35 | Hold | 13F |
| Warther Private Wealth, LLC | $31.9 Mil | 7.5% | 40 | ADD +5.7% | 13F |
| Generali Powszechne Towarzystwo Emerytalne | $24.4 Mil | 4.3% | 28 | Hold | 13F |
UNH Trade Sentinel
Constructive
CONVICTION RATIONALE
UnitedHealth is successfully executing a strategic pivot, trading near-term membership for improved profitability. Early results are positive, with the medical care ratio improving to 88.4% and 2026 earnings guidance raised to at least $20.50 per share. Conviction rests on management's ability to navigate cost pressures and return to its 13-16% long-term growth target in 2027.
STOCK ARCHETYPE
Diversified Healthcare PlatformRevenue = (Number of Members x Premium PMPM) + (Number of Patients x Fee-for-Service Rate) + (Script Volume x Price per Script) + Service & Tech Contract Value The ability to manage medical costs below premium revenues (the 'spread' in the insurance business) and the operating margins on high-volume pharmacy and technology services.
INVESTMENT THESIS
Evidence suggests a successful turnaround is underway, with pricing actions and cost controls improving profitability ahead of a planned 2027 growth re-acceleration.
- Q3 2026 medical care ratio improved to 88.4% from 89.9% year-over-year.
- Full-year 2026 adjusted EPS guidance was raised to at least $20.50.
- Management guides for a return to its 13%-16% long-term growth target in 2027.
- Operating margin of 5.3% remains superior to peers CVS (3.6%) and Cigna (3.2%).
- Optum Rx external membership now exceeds 50% for the first time.
PRIMARY RISK
Persistent Medicare Advantage underfunding and commercial cost trends exceeding 11% could erode margins faster than the company can reprice its business. This would invalidate the planned 2027 growth re-acceleration, leading to a period of stagnant earnings as the company is forced to continuously shed members to protect profitability.
- Medicare Advantage base rates have been 'well below' medical cost trends for years.
- Commercial cost trends are 'exceeding... expectations of 11%'.
- Trailing-twelve-month operating margin has compressed to 5.3% from 8.8% three years ago.
- The company served 1.8 million fewer people year-over-year as of Q3 2026.
- Latest-quarter revenue declined -0.4% year-over-year, reflecting membership losses.
| KPI | Status | Rationale |
|---|---|---|
| Total Medical Membership | Decelerating | The decline in membership is a deliberate strategy. Management is prioritizing profitability by exiting certain markets and repricing products, leading to a contraction in the number of people served. The Q3 2026 earnings call noted the company served 1.8 million fewer people year-over-year due to these benefit design and pricing actions. |
| Medical Care Ratio (MCR) | 88.4% for Q3 2026 - Turning around | The year-over-year improvement in MCR (a lower ratio is better) reflects successful cost management efforts. Management attributes the decrease to favorable prior period reserve development, affordability initiatives, pricing trends, and benefit design changes. The sequential increase from Q2 is expected due to business seasonality. |
| Total UnitedHealthcare - Medical Members | (As of 9/30/2026) | The total number of people served by UnitedHealthcare's medical plans is a primary driver of premium revenue. Membership declined year-over-year due to pricing actions and reduced Medicaid eligibility. |
| Optum Insight Backlog | $31.1 billion (As of 12/31/2025) | Represents estimated future revenue from signed contracts and other agreements, indicating the visibility of future revenue for the Optum Insight segment. A growing backlog signals strong demand for its services. |
| Optum Rx Adjusted Scripts | 393 million (Q3 2026) | The volume of prescriptions fulfilled, a key driver of revenue for the Optum Rx segment. Volume decreased from 414 million a year prior, reflecting membership contraction at UnitedHealthcare. |
Margin Pivot vs. Structural Headwinds
BULL VIEW
Bulls believe management's proven execution will successfully restore margins through disciplined pricing, allowing a profitable return to 13-16% growth in 2027 despite external cost pressures. The recent guidance raise and MCR improvement are early proof points.
CORE TENSION
Can pricing discipline, which improved the Q3 MCR to 88.4%, overcome structural Medicare funding gaps and commercial cost trends exceeding 11%?
PREVAILING SENTIMENT
The latest evidence favors the bull case. The Q3 MCR improved year-over-year, and management raised full-year 2026 adjusted EPS guidance to at least $20.50.
BEAR VIEW
Bears argue that persistent Medicare underfunding and commercial cost inflation above 11% are structural, not cyclical. They believe the current margin relief is temporary and that the company cannot out-price these headwinds without unacceptable market share loss.
| Timeline | Event & Metric To Watch |
|---|---|
In November 2026 | New Share Repurchase Authorization Watch: A new share repurchase program is authorized for up to 50 million shares of Common Stock. |
before year-end | Full Year 2027 Outlook Watch: The company will provide a comprehensive update on its outlook for the next year. |
1/25/2027 | Disappointing Medicare Advantage Guidance Watch: 2027 Medicare Advantage membership and margin guidance; any commentary on further benefit reductions or market exits. |
1/25/2027 | Persistent Commercial Cost Inflation Watch: Management's updated 2027 commercial medical cost trend forecast and its impact on pricing and margin targets. |
1/25/2027 | Negative Medicaid Rate Developments Watch: The 2027 Medicaid margin outlook and commentary on the status of state rate negotiations for key markets. |
1/25/2027 | Company Q4 Earnings Report Watch: UnitedHealth Group is scheduled to report Q4 2026 earnings. |
1/26/2027 - 2/9/2027 | Peer Read-Across on Costs Watch: Commentary on medical cost trends from peers, particularly in commercial and Medicare Advantage segments. |
2/3/2027 | Peer Cigna Earnings Report Watch: Peer Cigna (CI) is scheduled to report earnings. |
2/4/2027 | Peer Centene Earnings Report Watch: Peer Centene (CNC) is scheduled to report earnings. |
Beginning Dec. 1 | Pediatric Prior Authorization Eased Watch: Prior authorization will no longer be needed for more than 2,000 pediatric care codes. |
| Date | Event | Stock Impact |
|---|---|---|
2026-11-02 | Further Pediatric Care Simplification Details: UnitedHealthcare announced that beginning Dec. 1, prior authorization would no longer be needed for over 2,000 pediatric care codes, fast-tracking access to common services for children. | -0.6% $406.97 -> $404.44 |
2026-10-13 | Q3 Results Beat, Guidance Raised Details: The company reported third quarter 2026 results, beating expectations and raising its full-year 2026 adjusted EPS guidance to at least $20.50. The stock had a 5.0% positive two-day reaction. | +4.5% $378.52 -> $395.62 |
2026-09-24 | New Chief Administrative Officer Hired Details: Jodee Kozlak was appointed to the newly created role of Chief Administrative Officer, effective Sept. 28, 2026, to help drive enterprise modernization and alignment efforts. | +1.4% $371.29 -> $376.59 |
2026-08-12 | Quarterly Dividend Authorized Details: The Board of Directors authorized a quarterly cash dividend of $2.32 per share, which was paid on September 22, 2026. | -0.8% $399.73 -> $396.62 |
2026-07-16 | Q2 Earnings Beat, Guidance Raised Details: The company raised its full-year profit outlook after reporting second-quarter earnings that exceeded expectations, signaling that turnaround efforts were gaining traction. The stock reacted positively to the news. | +1.8% $415.96 -> $423.48 |
2026-05-29 | Pediatric Prior Authorization Reduced Details: UnitedHealthcare announced it would eliminate nearly two-thirds of prior authorization requirements for members under age 18 by year's end, as part of an initiative to simplify the healthcare system. | -0.7% $378.03 -> $375.39 |
Position Sizing
4% - 6%
NORMAL POSITION
Sizing is volatility-based: UNH trades at roughly 23% annualized realized (three-month) volatility versus about 10% for the S&P 500 (2.4x the market). A 4% - 6% position keeps a single-name swing of that size within a diversified portfolio's risk budget.
Diversification Alternatives
CVS - CVS Health
Vertical Integration PlayOffers a different model with a large retail pharmacy and store footprint, providing direct consumer access that UNH lacks. Its 14.2% gross margin is lower, reflecting this different business mix.
CI - Cigna
Focused PBM & ServicesProvides more concentrated exposure to the pharmacy benefit management and health services space through its Evernorth segment, without the large, regulated insurance balance sheet of UnitedHealthcare.
UNH is a two-part story: a massive, mature insurance business (UnitedHealthcare) generating cash to fund a higher-growth, integrated health services platform (Optum) that aims to bend the healthcare cost curve.
UNH is navigating a challenging period of elevated medical costs and government funding pressures by prioritizing margin stability over membership growth. The company is leveraging its scale and integrated Optum capabilities, particularly in data analytics and AI, to modernize operations, reduce administrative friction, and improve care management. This strategic repositioning, while causing near-term revenue and membership headwinds, is intended to build a more sustainable and profitable foundation for growth in 2027 and beyond.
News of stabilizing or declining medical cost trends, successful repricing leading to margin expansion in UnitedHealthcare, and accelerated adoption of Optum's AI-driven services by third-party payers.
Sustained high medical cost inflation that outpaces pricing actions, further cuts to Medicare Advantage funding, or an inability for Optum Health to return to target profitability margins.
Short-term quarterly membership fluctuations, given the explicit strategy to trade some growth for margin. Minor legal proceedings that do not fundamentally alter business practices.
Repricing Catalyst
The market's reaction to the Q3 2026 earnings, which showed progress on cost management and margin recovery, leading to a raised full-year EPS guidance and positive management commentary on the 2027 outlook.
UnitedHealthcare
$687.1B TTM (77% of Total) · 2% MarginWhat It Is
Offers a range of health benefit plans to national employers, public sector employers, mid-sized and small businesses, individuals, and Medicare and Medicaid beneficiaries.
Who Pays & How
Employers, individuals, and government agencies (CMS for Medicare, states for Medicaid) pay monthly premiums to assume the financial risk of healthcare costs and gain access to a discounted network of providers and care management services.
Competition
Optum Health
$198.6B TTM (22% of Total) · 0% MarginWhat It Is
Provides patient-centered care delivery, including primary, specialty, and surgical care, as well as care management and health financial services. It serves 95 million consumers and over 100 health payer partners.
Who Pays & How
Payers (health plans, employers, government entities) and patients pay for services. Payers enter into value-based arrangements, paying a monthly premium for Optum Health to assume responsibility for healthcare costs, aiming for better outcomes and lower total cost.
Competition
Optum Insight
$39.5B TTM (4% of Total) · 8% MarginWhat It Is
Sells data, analytics, research, consulting, technology, and managed services to hospital systems, physicians, health plans, governments, and life sciences companies.
Who Pays & How
Health systems, health plans, and other healthcare participants pay for solutions that simplify administrative and clinical processes, improve performance, reduce costs, and meet compliance mandates.
Competition
Optum Rx
$296.6B TTM (33% of Total) · 2% MarginWhat It Is
Provides a full spectrum of pharmacy care services, including retail pharmacy networks, home delivery, and specialty pharmacy, to health benefits providers, employers, unions, and public-sector entities.
Who Pays & How
Health plans and employers pay for pharmacy benefit management (PBM) services to control prescription drug costs and ensure members have access to medications. Revenue includes the cost of pharmaceuticals, dispensing fees, and customer co-payments.
Competition
UnitedHealth Group — Investor Video Playlist
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.